The rate of upgrade to cancer for breast lesions with uncertain malignant potential (B3 lesions) diagnosed at needle biopsy is highly influenced by several factors, but large series are sel-dom available. We retrospectively assessed the upgrade rates of a consecutive series of B3 lesions diagnosed at ultrasound‐ or mammography‐guided vacuum‐assisted biopsy (VAB) at an EU‐ SOMA‐certified Breast Unit over a 7‐year timeframe. The upgrade rate was defined as the number of ductal carcinoma in situ (DCIS) or invasive cancer at pathology after excision or during follow-up divided by the total number of B3 lesions. All lesions were reviewed by one of four pathologists with a second opinion for discordant assessments of borderline cases. Excision or surveillance were defined by the multidisciplinary tumor board, with 6‐ and 12‐month follow‐up. Out of 3634 VABs (63% ultrasound‐guided), 604 (17%) yielded a B3 lesion. After excision, 17/604 B3 lesions were finally upgraded to malignancy (2.8%, 95% confidence interval [CI] 1.8–4.5%), 10/17 (59%) being upgraded to DCIS and 7/17 (41%) to invasive carcinoma. No cases were upgraded during follow‐up. B3a lesions showed a significantly lower upgrade rate (0.4%, 95% CI 0.1–2.1%) than B3b lesions (4.7%, 95% CI 2.9–7.5%, p = 0.001), that had a 22.0 adjusted odds ratio for upgrade (95% CI 2.1–232.3). No significant difference was found in upgrade rates according to imaging guidance or needle cal-iper. Surveillance‐oriented management can be considered for B3a lesions, while surgical excision should be pursued for B3b lesions.
B3 Lesions at Vacuum-Assisted Breast Biopsy under Ultrasound or Mammography Guidance: A Single-Center Experience on 3634 Consecutive Biopsies / V. Girardi, M. Guaragni, N. Ruzzenenti, F. Palmieri, G. Fogazzi, A. Cozzi, D. Lucchini, A. Buffoli, S. Schiaffino, F. Sardanelli. - In: CANCERS. - ISSN 2072-6694. - 13:21(2021 Nov 01), pp. 5443.1-5443.12. [10.3390/cancers13215443]
B3 Lesions at Vacuum-Assisted Breast Biopsy under Ultrasound or Mammography Guidance: A Single-Center Experience on 3634 Consecutive Biopsies
A. Cozzi
;F. SardanelliUltimo
2021
Abstract
The rate of upgrade to cancer for breast lesions with uncertain malignant potential (B3 lesions) diagnosed at needle biopsy is highly influenced by several factors, but large series are sel-dom available. We retrospectively assessed the upgrade rates of a consecutive series of B3 lesions diagnosed at ultrasound‐ or mammography‐guided vacuum‐assisted biopsy (VAB) at an EU‐ SOMA‐certified Breast Unit over a 7‐year timeframe. The upgrade rate was defined as the number of ductal carcinoma in situ (DCIS) or invasive cancer at pathology after excision or during follow-up divided by the total number of B3 lesions. All lesions were reviewed by one of four pathologists with a second opinion for discordant assessments of borderline cases. Excision or surveillance were defined by the multidisciplinary tumor board, with 6‐ and 12‐month follow‐up. Out of 3634 VABs (63% ultrasound‐guided), 604 (17%) yielded a B3 lesion. After excision, 17/604 B3 lesions were finally upgraded to malignancy (2.8%, 95% confidence interval [CI] 1.8–4.5%), 10/17 (59%) being upgraded to DCIS and 7/17 (41%) to invasive carcinoma. No cases were upgraded during follow‐up. B3a lesions showed a significantly lower upgrade rate (0.4%, 95% CI 0.1–2.1%) than B3b lesions (4.7%, 95% CI 2.9–7.5%, p = 0.001), that had a 22.0 adjusted odds ratio for upgrade (95% CI 2.1–232.3). No significant difference was found in upgrade rates according to imaging guidance or needle cal-iper. Surveillance‐oriented management can be considered for B3a lesions, while surgical excision should be pursued for B3b lesions.File | Dimensione | Formato | |
---|---|---|---|
Girardi et al. - 2021.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
265.82 kB
Formato
Adobe PDF
|
265.82 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.